{
 "@context" : "http://schema.org",
  "id" : "http://bio2rdf.org/drugbank:DB00092",
  "type" : "Drug",
  "clinicalPharmacology" : "Interferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction. Activation of T lymphocytes involving the interaction between LFA-3 on antigen-presenting cells and CD2 on T lymphocytes plays a role in the pathophysiology of chronic plaque psoriasis. Also causes a reduction in subsets of CD2+ T lymphocytes as well as CD4+ and CD8+ T lymphocytes.",
  "cost" : {
    "id" : "http://bio2rdf.org/drugbank_resource:7afa1800e5c1c46512e6ca6d36734f9b",
    "type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "1190.4000244140625",
    "drugUnit" : "Amevive 15 mg vial"
  },
  "description" : "Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.",
  "drugClass" : [ "Dermatologic Agents", "Immunosuppressive Agents" ],
  "schema:identifier" : "drugbank:DB00092",
  "legalStatus" : [ "Withdrawn", "Approved" ],
  "mechanismOfAction" : "Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen.",
  "name" : "Alefacept",
  "nonProprietaryName" : "ASP0485",
  "proprietaryName" : "Amevive",
  "sameAs" : [ "http://www.rxlist.com/cgi/generic3/amevive.htm", "http://www.drugbank.ca/drugs/DB00092", "http://www.drugs.com/cdi/alefacept.html" ],
  "schema:url" : "http://bio2rdf.org/drugbank:DB00092"
}